May 21, 2015 @ 4:00 pm
Evans Hall, School of Management Yale
Yale University
165 Whitney Avenue, New Haven, CT 06511


“For too many entrepreneurs and early-stage companies, outreach means two things: (1) a love-hate-need relationship with equity investors, and (2) praying on the altar of big pharma. Most rarely spend time in two critical habitats populated by critical stakeholders: venture philanthropy and government relations. These parts of the entrepreneurial ecosystem can provide funding where few deals have deal sheets; where support and value-add go far beyond the money. And, after an initial “tranche” of interest, they can be there throughout the medical product continuum. Their patients are your market. Their constituents are your market. Avoid them at your own peril.”

About Dr. Michael Salgaller:

michael-cure-learnDr. Michael Salgaller has over 20 years of medical research, business, and investment experience in various life science sectors. He provides technical and strategic expertise to The Conafay Group in the area of funding, alliance development, and government relations.

Prior to joining The Conafay Group, he was a key member of the business development team for the healthcare practice at SAIC/Leidos – a Fortune-500 government contractor with $10B in annual revenue. He helped lead and deepen relationships with the Department of Health and Human Services – especially NIH and FDA – as well as foundations and patient advocacy groups. Before SAIC, he was a long-time industry executive who has held various positions in biotechnology and professional service firms – including interim President of Biologics Consulting Firm – a boutique medical product consulting firm. He was on the investment team of Toucan Capital, a $120M early-stage venture firm dedicated to the life sciences – where he guided company formation and helped develop medical products. Before that, as Vice President of Clinical and Research Affairs at Northwest Biotherapeutics, he led the development of two cancer treatments currently in late-stage clinical trials. He began his career doing bench research: as a Senior Staff Scientist at the National Cancer Institute, where he oversaw a laboratory developing cancer treatments for patients with terminal illnesses.

He is an author of over 100 articles, presentations, and book chapters, and serves on the editorial boards of several journals. He is the author of “Biotechnology Entrepreneurship,” which is used as a reference text for courses at NIH, Catholic University, and others. For several years, he has served on the selection committee for Maryland’s Incubator Company of the Year Awards, as well the Maryland Biotechnology Center Grant Awards. He was elected to the Sigma Xi Research Honorary, as well as the Pi Delta Epsilon Journalism Honorary. Dr. Salgaller received his PhD in Pathology from The Ohio State University.